Compare TNXP & FLNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | FLNT |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 82.2M |
| IPO Year | 2008 | 2009 |
| Metric | TNXP | FLNT |
|---|---|---|
| Price | $5.24 | $3.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $39.00 | $5.00 |
| AVG Volume (30 Days) | ★ 1.0M | 48.2K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | 41.67 |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $208,764,000.00 |
| Revenue This Year | $325.44 | $2.21 |
| Revenue Next Year | $99.29 | $14.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $4.96 | $1.70 |
| 52 Week High | $20.56 | $4.49 |
| Indicator | TNXP | FLNT |
|---|---|---|
| Relative Strength Index (RSI) | 21.32 | 69.39 |
| Support Level | N/A | $3.39 |
| Resistance Level | $13.73 | $3.51 |
| Average True Range (ATR) | 0.37 | 0.23 |
| MACD | 0.14 | 0.11 |
| Stochastic Oscillator | 16.18 | 78.51 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.